纤维样肾小球病 中国就医指南

Fibrillary glomerulopathy (FG) is a rare, progressive kidney disease characterized by the deposition of non-amyloid, randomly oriented fibrils (10–30 nm in diameter) within the glomerular basement membrane and mesangium. These fibrils are composed primarily of immunoglobulin G (IgG), often with kappa light chain predominance, and lack the beta-pleated sheet conformation seen in amyloidosis—distinguishing FG from amyloid nephropathy both histologically and biochemically. Pathogenesis remains incompletely understood but is thought to involve dysregulated immune responses, abnormal IgG folding or post-translational modification, and chronic antigenic stimulation; autoimmunity and monoclonal gammopathy are frequently associated, though most cases are idiopathic. Electron microscopy is essential for definitive diagnosis, as light and immunofluorescence microscopy may show nonspecific findings such as mesangial expansion, capillary wall thickening, and granular IgG/C3 deposits. Clinically, FG typically presents in adults aged 50–70 years, with insidious onset of proteinuria (often nephrotic-range), microscopic hematuria, hypertension, and gradually declining estimated glomerular filtration rate (eGFR). Approximately 30–40% of patients progress to end-stage kidney disease (ESKD) within 5–10 years of diagnosis without intervention. Epidemiologically, FG accounts for <1% of native kidney biopsies in large referral centers and is significantly rarer than other primary glomerulopathies like membranous nephropathy or IgA nephropathy. No clear gender predilection exists, though some cohort studies suggest a slight male predominance. Known risk factors include chronic hepatitis C infection (in a subset), autoimmune disorders (e.g., Sjögren’s syndrome, rheumatoid arthritis), and monoclonal gammopathy of undetermined significance (MGUS); however, over 60% of cases have no identifiable systemic association. Quality of life is substantially impacted: persistent edema, fatigue, recurrent infections due to hypoalbuminemia and immunosuppression, thromboembolic events, and anxiety surrounding unpredictable renal decline contribute to physical disability, work impairment, and psychosocial burden. Patients often require long-term monitoring, dietary restrictions (low-sodium, moderate-protein), diuretic therapy, anticoagulation, and eventual consideration of renal replacement therapy. The absence of standardized treatment guidelines further complicates care coordination and patient empowerment.

# 纤维样肾小球病治疗方案与费用明细（肾内科）

一、非手术/保守治疗方案

适用人群：确诊早期、eGFR ≥60 mL/min/1.73m²、无显著肾病综合征或心衰者。

• •基础药物治疗：沙库巴曲缬沙坦（ARB替代）、环磷酰胺（口服）+糖皮质激素（泼尼松），月均药费：¥2,800–¥5,200
• •支持治疗：低蛋白饮食指导、利尿剂（呋塞米）、降脂（阿托伐他汀）、ACEI/ARB肾保护，月均药费：¥600–¥1,500
• •监测检验费（每3个月）：24h尿蛋白定量、血清游离轻链（κ/λ）、肾功能、肝功、骨髓活检（初筛必需），单次：¥2,100–¥3,400

二、核心介入/免疫清除方案

适用人群：中重度蛋白尿（>3.5g/d）、血清轻链升高、进展性肾功能下降（eGFR下降≥3mL/min/年）。

• •血浆置换（PE）+硼替佐米+地塞米松方案（6周期）：含术前评估（心脏超声、凝血四项、中心静脉置管）、每次PE耗材+人工费，全程费用：¥86,000–¥132,000
• •自体干细胞移植（ASCT）（仅限AL型淀粉样变合并者）：预处理+回输+住院监护，总费用：¥280,000–¥390,000

三、晚期/耐药/并发症方案

终末期（eGFR <15）、透析依赖或严重心肌浸润者：

• •维持性血液透析（每周3次）+靶向抗纤维化试验性治疗（如NEOD001临床试验入组），年均费用：¥120,000–¥180,000（含透析、并发症管理、营养支持）

方案快速选择指南

• •预算≤¥5万/年+早期患者 → 保守药物+规范随访
• •预算¥8–15万+中高危进展者 → 血浆置换联合化疗
• •预算≥¥25万+AL型合并症明确者 → ASCT评估优先
• •已透析/多器官受累 → 多学科MDT制定个体化姑息与支持方案